Replies to post #121388 on Biotech Values

[exwannabe]

It;s interesting that fondaparinux received a priority review(dont know the basis?) by FDA. One would think copaxone being such a heavily used product, would also necessitate a priority review.

Priority reviews are part of the PDUFA act that applies to NDA/BLAs, but not ANDAs.